Masimo (NASDAQ:MASI) Issues Q3 Earnings Guidance

Masimo (NASDAQ:MASI) updated its third quarter earnings guidance on Wednesday. The company provided EPS guidance of $0.81-0.86 for the period, compared to the consensus EPS estimate of $0.84. The company issued revenue guidance of $495-515 million, compared to the consensus revenue estimate of $502.48 million. Masimo also updated its Q3 2024 guidance to 0.810-0.860 EPS.

Analyst Upgrades and Downgrades

A number of equities analysts recently commented on the company. Piper Sandler lifted their price objective on Masimo from $160.00 to $165.00 and gave the stock an overweight rating in a research report on Wednesday, August 7th. Needham & Company LLC reiterated a hold rating on shares of Masimo in a report on Friday, September 20th. Four equities research analysts have rated the stock with a hold rating and four have assigned a buy rating to the stock. Based on data from MarketBeat, the company has an average rating of Moderate Buy and a consensus price target of $144.67.

Masimo Price Performance

MASI stock opened at $133.10 on Friday. Masimo has a 52-week low of $75.22 and a 52-week high of $153.93. The company has a quick ratio of 1.15, a current ratio of 2.09 and a debt-to-equity ratio of 0.55. The stock has a market cap of $7.08 billion, a price-to-earnings ratio of 90.54 and a beta of 0.98. The business has a fifty day moving average of $116.67 and a two-hundred day moving average of $124.97.

Masimo (NASDAQ:MASI) last issued its quarterly earnings data on Tuesday, August 6th. The medical equipment provider reported $0.86 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.77 by $0.09. Masimo had a return on equity of 14.07% and a net margin of 3.94%. The firm had revenue of $496.30 million during the quarter, compared to the consensus estimate of $493.92 million. During the same period last year, the company earned $0.62 EPS. The company’s quarterly revenue was up 9.0% on a year-over-year basis. As a group, research analysts anticipate that Masimo will post 3.87 earnings per share for the current year.

Masimo Company Profile

Masimo Corporation develops, manufactures, and markets various patient monitoring technologies, and automation and connectivity solutions worldwide. The company offers masimo signal extraction technology (SET) pulse oximetry with measure-through motion and low perfusion pulse oximetry monitoring to address the primary limitations of conventional pulse oximetry; Masimo rainbow SET platform, including rainbow SET Pulse CO-Oximetry products that allows noninvasive monitoring of carboxyhemoglobin, methemoglobin, hemoglobin concentration, fractional arterial oxygen saturation, oxygen content, pleth variability index, rainbow pleth variability index, respiration rate from the pleth, and oxygen reserve index, as well as acoustic respiration monitoring, SedLine brain function monitoring, NomoLine capnography and gas monitoring, and regional oximetry.